Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

NCT03191149 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03191149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03191149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
April 25, 2018
Completion date
June 30, 2027
Enrollment
46 (estimated)
Sites
347

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iiib lung non-small cell cancer ajcc v7, stage iv lung non-small cell cancer ajcc v7